Opinion

Video

Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

Author(s):

Shubham Pant, MD,Haley Ellis, MD

Panelists discuss how the practice-changing TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as a first-line standard for advanced biliary tract cancer (BTC) while exploring key clinical factors that influence the choice between durvalumab and pembrolizumab-based combinations following the KEYNOTE-966 results.

Video content above is prompted by the following:

  • Moving into first-line treatment options for advanced BTC, can you briefly describe the TOPAZ-1 trial and how these results impacted your clinical practice?
  • Another checkpoint inhibitor combination is with pembrolizumab from the KEYNOTE-966 trial. What factors do you consider when selecting between a durvalumab vs pembrolizumab combination?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content